A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

NCT03785184 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Strategic considerations

Conditions

Multiple Myeloma

Interventions

DRUG: venetoclax
DRUG: lenalidomide
DRUG: dexamethasone

Sponsor

AbbVie

Collaborators

[object Object]
[object Object]